News · Supplements
Vitamin D missed its target in depressed young people
A trial gave 4,800 IU a day for eight weeks to young people who had both major depression and low vitamin D, the group where it should work best. Depression scores did not separate from placebo. Anxiety did.
- Low vitamin D is common in people with depression, which is why the supplement gets tried.
- 108 people aged 10 to 24 with major depression and low vitamin D, 8 weeks of 4,800 IU a day.
- Primary outcome, clinician-rated depression: no difference from placebo (B -0.30).
- Anxiety scores did fall (B -1.78; 95% CI -3.35 to -0.32), a secondary outcome.
- A moderate-to-severe subgroup improved, and adolescents in that subgroup did not.
The vitamin D and depression idea rests on a simple premise: the two turn up in the same people often enough to suggest a link, and the supplement is cheap and safe.
Trials keep coming back mixed, and one recurring explanation is that they recruited the wrong people: give vitamin D to somebody who already has plenty and nothing should happen.
A trial in the European Journal of Nutrition removed that excuse. It recruited young people who had both major depression and low vitamin D, dosed them at 4,800 IU, or international units, a day, and measured what happened.
The depression scores did not move.
What vitamin D does, and where mood is not on the list
Vitamin D helps your body absorb calcium. Calcium is one of the main building blocks of bone. Your muscles need it to move, and your nerves need it to carry messages between your brain and your body.
That last function is where the mood hypothesis attaches: a vitamin the nervous system uses, low in people who are depressed.
Notably, the MedlinePlus page on vitamin D contains no information about vitamin D and mood or depression. The link is a research question rather than established guidance, which is worth knowing before reading any single trial.
Depression itself is one of the most common mental disorders in the United States, and it can cause severe symptoms that affect how you feel, think, and handle daily activities, such as sleeping, eating, or working.
How the vitamin D trial was designed
The trial enrolled outpatients aged 10-24 with major depression and vitamin D insufficiency/deficiency, which is the population where a deficiency-correction effect should be easiest to see.
The design is unusual and worth understanding. This was a partially randomized patient preference trial: participants who expressed a preference received vitamin D, while others were randomly assigned to vitamin D or placebo groups.
That produces three groups: randomized vitamin D (RVD, n = 41), preference vitamin D (PVD, n = 28), and placebo (PL, n = 39). Only the randomized comparison carries the protection randomization offers; the preference arm is chosen, and people who choose a supplement differ from people who do not.
Randomization was performed using computer-generated random numbers in blocks of four, with allocation concealed from researchers, participants, and treating physicians. Supplementation groups received 4,800 IU of vitamin D3 daily for 8 weeks.
What the depression scores did
The primary outcome was assessor-rated depressive symptoms measured using the 17-item Hamilton Depression Rating Scale, where a trained assessor rates the patient rather than the patient rating themselves.
There was no significant difference in depression between the RVD and PL groups. The randomized vitamin D group and the placebo group ended in the same place, and the range around that difference sits squarely across zero.
Anxiety went the other way. Anxiety was reduced in the RVD group, on a self-reported scale, by a margin the study could distinguish from chance.
That is one positive result among the secondary outcomes, in a trial whose main question came back empty.
Why the vitamin D subgroup finding needs care
The paper reports a further result that will do most of the traveling. Subgroup analyses revealed that the participants with moderate-to-severe depression in the RVD groups had reduced depression and anxiety versus placebo.
Read on for the sentence that undercuts it. However, the subgroup of adolescents with moderate-to-severe depression did not differ in all outcome scores in the RVD versus placebo.
So the effect appears when you select the more severely depressed participants, and vanishes when you look at the younger half of that same group. Subgroups get smaller as you slice them, and small groups produce unstable results in both directions.
The authors are unusually direct about this. While sample size constraints favor an exploratory interpretation of these findings, this study provides a valuable piece of the puzzle; future trials are essential to complete the clinical picture.
What 108 people over eight weeks cannot show
A hundred and eight participants across three arms leaves roughly forty per group, which is enough to detect a large effect and not a modest one. A null result here does not prove vitamin D does nothing; it shows this trial could not find anything.
Eight weeks is also short for depression, where antidepressants are typically judged at six to twelve.
The preference arm complicates interpretation further, since those participants chose their treatment and may differ in expectation, adherence and outlook.
The paper is paywalled, so the authors’ own limitations section was not available beyond the exploratory framing in the abstract.
What to do if your vitamin D is low
Correcting a genuine deficiency is worth doing on its own terms. A lack of vitamin D can lead to bone diseases such as osteoporosis or rickets, and older adults, people with dark skin and people with obesity are among those at higher risk of low levels.
What this trial argues against is treating the supplement as an antidepressant. In the group where it had the best chance of working, on the outcome the trial was built to measure, it did not beat a placebo.
The safety picture was reassuring as far as it went: no differences in hypercalcemia or hyperphosphatemia were observed.
If depression is the problem, the treatments with evidence behind them are the ones to ask a doctor about first.
People also ask
What was the primary outcome, and what happened to it?
The primary outcome was assessor-rated depressive symptoms measured using the 17-item Hamilton Depression Rating Scale. There was no significant difference in depression between the randomized vitamin D and placebo groups (B -0.30; 95% CI -1.81 to 1.21; p = 0.698). That is the result the trial was designed to produce, and it is a null.
What did improve?
Anxiety was reduced in the randomized vitamin D group (B -1.78; 95% CI -3.35 to -0.32; p = 0.026), measured on the Generalized Anxiety Disorder-7 scale. That was a secondary outcome. Subgroup analyses revealed that the participants with moderate-to-severe depression in the vitamin D groups had reduced depression and anxiety versus placebo.
Why does the subgroup result not settle it?
Because subgroups are where chance findings live, and this one contradicts itself internally: the subgroup of adolescents with moderate-to-severe depression did not differ in all outcome scores versus placebo. A signal that appears in a severity subgroup and disappears when you look at the younger half of it is a lead, not a finding.
What is a partially randomized patient preference trial?
An unusual design. Participants who expressed a preference received vitamin D, while others were randomly assigned to vitamin D or placebo groups. So the trial has three arms: randomized vitamin D (41 people), preference vitamin D (28), and placebo (39). Only the randomized comparison is protected from the differences between people who chose the supplement and people who did not.
Was the dose high enough?
It was substantial. Supplementation groups received 4,800 IU of vitamin D3 daily for 8 weeks, several times the usual maintenance dose, in people already known to have insufficient or deficient levels. If the dose were the problem, this design was set up to avoid it.
Was it safe?
On the measures reported, yes. No differences in hypercalcemia or hyperphosphatemia were observed, meaning blood calcium and phosphate did not rise abnormally in the supplement groups. Eight weeks is short, and high-dose vitamin D over longer periods carries its own considerations.
Should someone with depression take vitamin D?
Not as a treatment for depression on the strength of this. This is general information rather than medical advice. If a blood test shows you are deficient, correcting that is worth doing for bone and muscle reasons regardless of mood. What this trial argues against is expecting the depression itself to lift, and against stopping or delaying treatments that do work.
References
- Lee, Y.-T., Huang, H.-C., Ko, K.-T., et al. The impact of vitamin D supplementation on depression and anxiety in young individuals with depression and vitamin D insufficiency/deficiency. European Journal of Nutrition, 2026.
- MedlinePlus. Vitamin D. US National Library of Medicine.
- National Institute of Mental Health. Depression. US National Institutes of Health.